Patent Yard Sign in
Canadian application, no grantCanada

Npc1l1 (npc3) and methods of use thereof

CA 2492017 A1 · Owner: Murgolo, Nicholas J. · Inventors: Graziano, Michael P.; Wang, Lu Quan; Altmann, Scott W.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The present invention provides rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed July 17, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 17, 2023.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 17, 2025.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJuly 17, 2003
GrantedNo grant recorded
Term endedJuly 17, 2023
Patent numberCA 2492017 A1
Classification (IPC)C12N15/12 +2 more

Timeline

Timeline From CIPO dates

2004200620082010201220142016201820202022Application filedJuly 17, 2003Term endedJuly 17, 2023

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.